摘要 |
The present invention provides a method of treating or preventing complement-mediated immune disease in a subject, comprising administering to the subject an inhibitor of synthesis or activity of Factor B, whereby the inhibition of synthesis or activity of Factor B treats or prevents the immune disease. Also provided are an antibody to Factor B, an anti-sense oligonucleotide which blocks the mRNA which encodes Factor B and a peptide which competitively binds C3, the receptor for Factor B. The present invention further provides a vector comprising the nucleic acid of this invention and a cell comprising the vector. Also provided is a method of administering to a subject in a pharmaceutically acceptable carrier an antibody, oligonucleotide, peptide and vector of the invention. The present invention further provides a method of determining the predisposition of a subject to complement-mediated immune disease and a method of determining efficacy of treatment in and prognosis of a subject with complement-mediated immune disease. Further, the present invention also provides a mutant transgenic mouse. |